PMID- 20497490
OWN - NLM
STAT- MEDLINE
DCOM- 20110826
LR  - 20240322
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 15
IP  - 4
DP  - 2011 Apr
TI  - Mitogen activated protein kinase at the nuclear pore complex.
PG  - 928-37
LID - 10.1111/j.1582-4934.2010.01093.x [doi]
AB  - Mitogen activated protein (MAP) kinases control eukaryotic proliferation, and 
      import of kinases into the nucleus through the nuclear pore complex (NPC) can 
      influence gene expression to affect cellular growth, cell viability and 
      homeostatic function. The NPC is a critical regulatory checkpoint for 
      nucleocytoplasmic traffic that regulates gene expression and cell growth, and MAP 
      kinases may be physically associated with the NPC to modulate transport. In the 
      present study, highly enriched NPC fractions were isolated and investigated for 
      associated kinases and/or activity. Endogenous kinase activity was identified 
      within the NPC fraction, which phosphorylated a 30 kD nuclear pore protein. 
      Phosphomodification of this nucleoporin, here termed Nup30, was inhibited by 
      apigenin and PD-98059, two MAP kinase antagonists as well as with SB-202190, a 
      pharmacological blocker of p38. Furthermore, high throughput profiling of 
      enriched NPCs revealed constitutive presence of all members of the MAP kinase 
      family, extracellular regulated kinases (ERK), p38 and Jun N-terminal kinase. The 
      NPC thus contains a spectrum of associated MAP kinases that suggests an intimate 
      role for ERK and p38 in regulation of nuclear pore function.
CI  - (c) 2011 The Authors Journal of Cellular and Molecular Medicine (c) 2011 Foundation 
      for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
FAU - Faustino, Randolph S
AU  - Faustino RS
AD  - Institute of Cardiovascular Sciences, St Boniface Hospital Research Centre, and 
      Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, 
      Canada.
FAU - Maddaford, Thane G
AU  - Maddaford TG
FAU - Pierce, Grant N
AU  - Pierce GN
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - EC 3.1.3.16 (Phosphoprotein Phosphatases)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Cell Proliferation/drug effects
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Mitogen-Activated Protein Kinases/*metabolism
MH  - Myocytes, Smooth Muscle/cytology/enzymology
MH  - Nuclear Pore/drug effects/*enzymology
MH  - Phosphoprotein Phosphatases/metabolism
MH  - Phosphorylation/drug effects
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Subcellular Fractions/drug effects/enzymology
MH  - Substrate Specificity/drug effects
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
PMC - PMC3922677
EDAT- 2010/05/26 06:00
MHDA- 2011/08/30 06:00
PMCR- 2011/04/01
CRDT- 2010/05/26 06:00
PHST- 2010/05/26 06:00 [entrez]
PHST- 2010/05/26 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
PHST- 2011/04/01 00:00 [pmc-release]
AID - JCMM1093 [pii]
AID - 10.1111/j.1582-4934.2010.01093.x [doi]
PST - ppublish
SO  - J Cell Mol Med. 2011 Apr;15(4):928-37. doi: 10.1111/j.1582-4934.2010.01093.x.